Other

Idun Pharmaceuticals, Inc.

Respivant Sciences Gmbh

Ambit Biosciences Corporation

Thomas Jefferson University

Robert Craig Armstrong

Kevin J Tomaselli

Emad S Alnemri

Gerald Litwack

Teresa Fernandes-Alnemri

Pravin L Soni

William Gerhart

Lawrence C Fritz

Jose-Luis Diaz

Ahmet Tutuncu

Barbara A Belli

Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided.

Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders

The disclosure provides a method of treating pulmonary fibrosis, including idiopathic pulmonary fibrosis, in a comprising administering to the subject a pharmaceutical composition comprising from about 1% by weight to about 99% by weight of cromolyn sodium with an inhalation device.

Cromolyn compositions for treatment of pulmonary fibrosis

Provided herein are methods of treating a proliferative disease in a subject, comprising administering to the subject a therapeutically effective amount of AC220 and a nucleoside analog, a topoisomerase inhibitor or an anthracycline, or a combination thereof.

Methods of treatment using combination therapy

The invention provides an isolated gene encoding Mch4 or an isolated gene encoding Mch5 as well as functional fragments thereof. Also provided are isolated nucleic acid sequences encoding Mch4 or Mch5 or functional fragment thereof. The gene or nucleic acid sequences can be single or double stranded nucleic acids corresponding to coding or non-coding strands of the Mch4 or Mch5 nucleotide sequences. Also provided are genes and nucleic acids encoding functional fragments such as the FADD-like domains Mch4A, Mch4B, Mch5A and Mch5B. Isolated Mch4 or Mch5 polypeptides or functional fragments thereof including the FADD-like domains Mch4A, Mch4B, Mch5A and Mch5B are also provided.

Antibody that specifically binds an Mch5 polypeptide

Antibody that specifically binds an Mch4 polypeptide

The invention provides an isolated gene encoding Mch3, or functional fragment thereof. Also provided is an isolated nucleic acid sequence encoding Mch3 or functional fragment thereof. The gene or nucleic acid sequence can be single or double stranded nucleic acids corresponding to coding or non-coding strands of the Mch3 nucleotide sequence. An isolated Mch3 polypeptide or functional fragment thereof is also provided.

Mch3, a novel apoptotic protease, nucleic acids encoding and methods of use

The invention provides a single-well, microscale method of determining the specific apoptotic activity of a cell. The method consists of contacting a cell population of about 1&times;10 cells for a time period of between about 30 minutes and 4 hours with a sufficient volume of medium containing an apoptotic specific diagnostic reagent and a diagnostic accessory reagent so as to cover the cell population, and determining the activity of the apoptotic specific diagnostic reagent. The invention also provides a method of identifying a compound which induces apoptosis. The invention further provides a rapid method of identifying a compound which inhibits apoptosis.

Rapid methods for identifying modifiers of cellular apoptosis activity

The invention provides an isolated gene encoding Mch4 or an isolated gene encoding Mch5 as well as functional fragments thereof. Also provided are isolated nucleic acid sequences encoding Mch4 or Mch5 or functional fragment thereof The gene or nucleic acid sequences can be single or double stranded nucleic acids corresponding to coding or non-coding strands of the Mch4 or Mch5 nucleotide sequences. Also provided are genes and nucleic acids encoding functional fragments such as the FADD-like domains Mch4A, Mch4B, Mch5A and Mch5B. Isolated Mch4 or Mch5 polypeptides or functional fragments thereof including the FADD-like domains Mch4A, Mch4B, Mch5A and Mch5B are also provided.

Mch4 and Mch5, apoptotic protease, nucleic acids encoding and methods of use

The invention provides a single-well, microscale method of determining the specific apoptotic activity of a cell. In the various embodiments, the method comprising contacting a cell population of greater than about 10,000 to 1&times;10,cells for a time period of between about 30 minutes and 4 hours with a sufficient volume of medium containing an apoptotic specific diagnostic reagent and a diagnostic accessory reagent so as to cover the cell population, and determining the activity of the apoptotic specific diagnostic reagent. The invention also provides a method of identifying a compound which induces apoptosis. The invention further provides a rapid method of identifying a compound which inhibits apoptosis.

The invention provides a single-well, microscale method of determining the specific apoptotic activity of a cell. The method consists of contacting a cell population of about 1&times;10,cells for a time period of between about 30 minutes and 4 hours with a sufficient volume of medium containing an apoptotic specific diagnostic reagent and a diagnostic accessory reagent so as to cover the cell population, and determining the activity of the apoptotic specific diagnostic reagent. The invention also provides a method of identifying a compound which induces apoptosis. The invention further provides a rapid method of identifying a compound which inhibits apoptosis.

Growing community of inventors

San Diego, CA, United States of America

Robert Craig Armstrong